Norwegian biotechnology company Aker BioMarine has signed a long-term global supply agreement with Valensa International for the use of Superba™ in Krill Oil Joint Health and Eye Health products. It is said that in this endeavour Aker BioMarine will be the exclusive supplier of krill oil. The agreement states that Aker BioMarine and Valensa will also jointly perform clinical studies to document the unique properties of Superba™ Krill Oil as an ingredient in Valensa’s patented and patent-pending formulations.
Matts Johansen, Aker BioMarine’s EVP of Sales and Marketing, informed that they are delighted to have such opportunity working with Valensa, and this agreement marks the entry of Superba™ Krill Oil into the Joint Health market, the largest category of dietary supplements, representing USD 3.4 billion in US alone. Valensa said that it will use Superba™ Krill Oil in their condition-specific dietary supplement formulas in conjunction with several of their own proprietary ingredients, such as Zanthin® Natural Astaxanthin.
Valensa CEO Dr. Rudi E. Moerck told that the increased potency of formulas containing krill formulators and marketers to reduce the size of their softgels and reduce the ‘pill burden’ on people” as one of the key reasons for using Superba™ Krill Oil in Valensa’s proprietary formulations. Hallvard Muri, CEO of Aker BioMarine, opined that like Aker Valensa has taken a pharmaceutical-like approach to dietary supplements when it comes to quality and clinical documentation.
